Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.

Researchers said more should be done to weigh the pros and cons of taking weight loss drugs around the time of pregnancy.

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Researchers say a woman struggling with obesity who couldn't resist eating fatty foods experienced declines in her cravings after taking tirzepatide.

Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications. Waltz Health gave no information on the prices of GLP-1 drugs ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...